Conclusion: AKBR which reflects hepatic mitochondrial REDOX state is more reliable as direct indicator to assess hepatic tolerance for embolization therapy than routine liver function test.
结论：AKBR是直接反映肝损伤肝活力程度的一个量化指标，对判断肝脏对栓塞疗法的耐受程度及术后并发症的发生具有重要临床价值。
Blood routine examination, liver and function, electrocardiogram were monitored.
同时监测血常规、肝肾功能和心电图。
Patients with a marginal pretreatment liver function, as suspected after routine evaluation, may be further screened by hepatobiliary scintigraphy for improved treatment planning.
常规检查后怀疑术前肝功能不足患者，可通过肝胆动态显像进一步排查，以改进治疗方案。
The result of liver function, renal function, electrolyte, prothrombin time activity (PTa), blood routine before and after the treatment were analyzed.
比较了血浆置换前后患者临床症状、肝肾功能、电解质、凝血酶原活动度、血常规变化等。
No significant change of liver, renal function, blood sugar, blood lipid, electrolyte and blood routine test were occurred in carvedilol group.
最常见的不良反应是头晕，未出现肝、肾功能损害及血脂、血糖、电解质和血象的变化。
No abnormality in routine urine and liver and renal function examinations were found.
治疗过程中尿常规、肝肾功能均未见异常。
The clinical symptoms, routine blood count, liver and kidney functions, immune function, AFP, tumor focus, KPS score and survival period were compared before and after treatment.
比较治疗前后的临床症候、血常规、肝肾功能、免疫功能、AFP、肿瘤病灶及生活质量（KPS）评分的变化，并统计生存期。
Meanwhile, the blood routine, routine urine, feces routine, electrocardiogram (ECG), liver function, renal function, as safety indexes, were monitored too.
以血、尿、便常规，心、肝、肾功能及不良反应为安全性指标观察。
Methods Physiological index included blood and urine routine, ESR, liver function, renal function, and immunity items.
方法生理指标包括血尿常规、血沉、肝功能、肾功能、免疫项指标。
There were no remarkable effects in liver function, kidney function, blood and urine routine analysis, electrocardiography after taken torasemide for 8 weeks.
服用后8周实验药对肝肾功能、血尿常规及心电图均无明显影响。
There were no significant abnormalities in other signs, such as body weight, routine blood, liver function, kidney function, blood glucose and blood fat in all the patients involved in this test.
两组试食前后体重、血常规、肝功能、肾功能、血糖、血脂各项检测指标未见明显异常，试食过程中未出现明显不良反应。
There were no significant changes in blood routine, routine urine examination, blood sugar, blood lipid, liver function, renal function and ECG of two groups after treatment(P>0.05).
两组治疗前后血尿常规、血糖、血脂、肝功、肾功、心电图均无明显改变（P>0.05）。
At the same time detecting and recording routine, urine routine, blood glucose, liver function and renal function, ECG and adverse events before and after treatment.
同时检测和记录治疗前后血常规、尿常规、血糖、肝肾功能、心电图和不良事件。
At the same time detecting and recording routine, urine routine, blood glucose, liver function and renal function, ECG and adverse events before and after treatment.
同时检测和记录治疗前后血常规、尿常规、血糖、肝肾功能、心电图和不良事件。
应用推荐